- Home
- MIRA
as 07-26-2024 4:00pm EST
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 10.2M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 14.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $6.95 | Next Earning Date: | 09-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of MIRA Pharmaceuticals Inc. (MIRA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $1.00 | 2,000 | $2,000.00 | 375,500 | SEC Form 4 |
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $1.03 | 1,000 | $1,030.00 | 376,500 | SEC Form 4 |
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $1.02 | 500 | $510.00 | 377,000 | SEC Form 4 |
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $0.84 | 2,000 | $1,680.00 | 379,000 | SEC Form 4 |
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $0.85 | 1,000 | $850.00 | 380,000 | SEC Form 4 |
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $0.87 | 600 | $522.00 | 380,600 | SEC Form 4 |
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $1.01 | 800 | $808.00 | 381,400 | SEC Form 4 |
| Aminov Erez | MIRA | Chief Executive Officer | May 21 '24 | Buy | $0.97 | 800 | $776.00 | 382,200 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $5.07 | 13,367 | $67,764.01 | 2,845,951 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $5.00 | 2,500 | $12,500.00 | 2,843,451 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $4.00 | 3,213 | $12,859.71 | 2,840,238 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $4.00 | 121 | $484.00 | 2,840,117 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $3.98 | 3,699 | $14,720.54 | 2,836,418 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $3.77 | 2,421 | $9,136.37 | 2,833,997 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $3.98 | 30,665 | $122,046.70 | 2,803,332 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $2.95 | 13,867 | $40,893.78 | 2,789,465 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $1.89 | 16,666 | $31,577.07 | 2,772,799 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $1.61 | 9,526 | $15,315.90 | 2,763,273 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $1.55 | 23,003 | $35,748.96 | 2,740,270 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $5.07 | 13,366 | $67,758.94 | 765,681 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $5.00 | 2,500 | $12,500.00 | 763,181 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $4.00 | 3,212 | $12,855.71 | 759,969 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $4.00 | 120 | $480.00 | 759,849 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $3.98 | 3,700 | $14,724.52 | 756,149 | SEC Form 4 |
| McNulty Brian Patrick | MIRA | 10% Owner | Nov 20 '23 | Sell | $3.77 | 2,421 | $9,136.37 | 753,728 | SEC Form 4 |
Latest MIRA Pharmaceuticals Inc. News
MIRA Breaking Stock News: Dive into MIRA Ticker-Specific Updates for Smart Investing
Benzinga
a day ago
Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
ACCESSWIRE
2 days ago
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
Simply Wall St.
3 days ago
We're Not Very Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Rate
MT Newswires
4 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
4 days ago
MIRA Pharmaceuticals Shares Quadruple on More 'Promising' Ketamir-2 Study Results
Benzinga
4 days ago
Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders
ACCESSWIRE
5 days ago
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance
Zacks Small Cap Research
5 days ago
MIRA Posts More Positive Test Results
Compare MIRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRA MIRA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.